LENSAR Inc

LENSAR, Inc. engages in the development of femtosecond laser technology for refractive cataract surgery. Its product offers automation and customization options for astigmatism treatment planning and other steps of the refractive cataract surgery procedure. The company was founded by Scott Addyman, Randy W. Frey, and Ronald R. Krueger in 2004 and is headquartered in Orlando, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

LENSAR Inc (LNSR) reports strong Q1 growth and eyes global expansion

LENSAR Inc (LNSR) delivered robust financial performance in Q1 2024, marked by revenue and procedure growth, expansion of ALLY systems, and market share gains. While facing regulatory challenges and competition, the company's strong financial position and growth opportunities position it well for the future. Continued focus on innovation and market expansion will be key for sustained success.

LENSAR Inc (LNSR) reports robust Q3 earnings, eyes global expansion

LENSAR's Q3 2024 performance reflects strong growth momentum and operational improvements.
While challenges like cost management and market competition persist, the company's strategic strengths position it well for future opportunities.
By capitalizing on its successful international launch and focusing on revenue-driving strategies, LENSAR is poised for continued growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LENSAR, Inc. (LNSR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

LENSAR, Inc. (LNSR) Moves 13.5% Higher: Will This Strength Last?

LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of 31.67% and 31.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

LENSAR, Inc. (LNSR) Reports Q4 Loss, Tops Revenue Estimates

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2021 and provided an update on key strategic and operational initiatives. “2021 was a year of progress for LENSAR. Revenue and procedure volume in 2021 returned to our historical record of over 20% annu

LENSAR Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its 510(k) submission for its next-generation ALLY™ Adaptive Cataract Treatment System for substantive review. The submission seeks marketing clearance for the ALLY Adaptive Cataract Treatment System and i

LENSAR Announces U.S. Food and Drug Administration Acceptance of 510(k) Submission for ALLY

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2021 financial results will be released before market open on Thursday, March 3, 2022. LENSAR's management will host a conference call and webcast at 8:30am ET on Thursday, March 3, 2022 to discuss the financial results a

LENSAR to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect Conference. Mr. Curtis' presentation will be available on-demand beginning at 7:00 a.m. Eastern Time on Monday, January 10, 2022 and can be accessed through the Investors secti

LENSAR to Present at the H.C. Wainwright Virtual BioConnect Conference

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that two posters have been accepted for virtual presentation at the Annual Meeting of the American Academy of Ophthalmology (AAO) being held November 12-15, 2021. The titled presentations will be available on the AAO meeting portal starting on November 12, 2021: Femtos

LENSAR Announces Poster Presentations at the American Academy of Ophthalmology

LENSAR, Inc. (LNSR) CEO Nick Curtis on Q3 2021 Results - Earnings Call Transcript

LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of -10.17% and 7.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

LENSAR, Inc. (LNSR) Reports Q3 Loss, Tops Revenue Estimates

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended September 30, 2021 and provided an update on key strategic and operational initiatives. “The third quarter was one of continued progress on both the commercial and research and development aspects of our business. Our commercial

LENSAR Reports Third Quarter 2021 Financial Results and Provides Business Update

LENSAR, Inc. (LNSR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will LENSAR, Inc. (LNSR) Report Negative Q3 Earnings? What You Should Know

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's third quarter 2021 financial results will be released before market open on Monday, November 8, 2021. LENSAR's management will host a conference call and webcast at 8:30am ET on Monday, November 8, 2021 to discuss the financial results and recent cor

LENSAR to Report Third Quarter 2021 Financial Results on Monday, November 8, 2021

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the H.C. Wainwright 23rd Annual Global Investment Conference. Mr. Curtis' presentation will be available on-demand beginning at 7:00 a.m. Eastern Time on Monday, September 13, 2021 and can be accessed through th

LENSAR to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. Mr. Curtis' presentation will be available on-demand beginning at 7:00 a.m. Eastern Time on August 17, 2021 and can be accessed through th

LENSAR to Present at the H.C. Wainwright Ophthalmology Virtual Conference

LENSAR, Inc. (LNSR) CEO Nick Curtis on Q2 2021 Results - Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2021 and provided an update on key strategic and operational initiatives. “We have made significant progress across a number of fronts. Our commercial operations have rebounded from the COVID-19 pandemic, and we have ret

LENSAR Reports Second Quarter 2021 Financial Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's second quarter 2021 financial results will be released before market open on Thursday, August 5, 2021. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, August 5, 2021 to discuss the financial results and recent c

LENSAR to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced a total of 12 abstracts highlighting LENSAR's technology have been accepted for presentation at the 2021 Annual Meeting of the American Society of Cataract and Refractive Surgeons, being held July 23-27, 2021 in Las Vegas, NV. In addition to these presentations, the Co

LENSAR Announces In-Person Demonstrations of Its Next Generation ALLY™ System and Multiple Data Presentations at the American Society of Cataract and Refractive Surgery (ASCRS) 2021 Annual Meeting

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the Oppenheimer MedTech, Tools, & Diagnostics Summit on May 26, 2021. Mr. Curtis' presentation will be available on-demand beginning at 8:00 a.m. Eastern Time on May 26, 2021 and can be accessed through the

LENSAR to Present at the Oppenheimer MedTech, Tools, & Diagnostics Summit

LENSAR, Inc. (LNSR) CEO Nick Curtis on Q1 2021 Results - Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the first quarter ended March 31, 2021 and provided an update on key strategic and operational initiatives. “2021 is off to an encouraging start as we have continued to build on the positive trends seen in the second half of last year and achieved

LENSAR Reports First Quarter 2021 Financial Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's first quarter 2021 financial results will be released before market open on Wednesday, May 5, 2021. LENSAR's management will host a conference call and webcast at 8:30 am ET on Wednesday, May 5, 2021 to discuss the financial results and recent corpor

LENSAR to Hold First Quarter 2021 Financial Results Conference Call on Wednesday, May 5, 2021

LENSAR's (LNSR) CEO Nick Curtis on Q4 2020 Results - Earnings Call Transcript

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on key strategic and operational initiatives. “2020 was a transformative year for LENSAR,” said Nick Curtis, Chief Executive Officer of LENSAR. “Despite the unpreceden

LENSAR Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2020 financial results will be released before market open on Wednesday, March 10, 2021. LENSAR's management will host a conference call and webcast at 8:30 am ET on Wednesday, March 10, 2021 to discuss the financial resu

News for LENSAR Inc Stock (LNSR)